Evaluation of the Frequency of Limitation of Activity in Patients With Persistent Asthma

Overview

Evaluation of the frequency of limitation of activity, depending on gender and age-group, in patients with persistent asthma consulting a general practitioner

Full Title of Study: “Evaluation of the Frequency of Limitation of Activity, Depending on Gender and Age-group, in Patients With Persistent Asthma Consulting a General Practitioner”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Cross-Sectional
  • Study Primary Completion Date: October 2010

Clinical Trial Outcome Measures

Primary Measures

  • To describe the frequency of limitations of activities in patients with persistent asthma depending on gender and age-group.
    • Time Frame: Last 3 months / once
  • To describe, depending on gender and age-group, the nature of the activities limited, the degree of limitation and the impact on the patient’s daily life.
    • Time Frame: Once during only visit

Secondary Measures

  • To describe the nature of the activities limited, the degree of limitation and the impact on the patient’s daily life according to the level of asthma control
    • Time Frame: Once during only visit
  • To describe, depending on gender and age-group, the activities that need to be specifically investigated in routine clinical practice due to their greater impact on the patient’s quality of life, and which could indicate poorly controlled asthma
    • Time Frame: Once during only visit
  • To describe the main characteristics and initial management for all patients of the survey
    • Time Frame: Once during only visit

Participating in This Clinical Trial

Inclusion Criteria

  • persistent asthma receiving long-term maintenance treatment with inhaled steroids (alone or in combination with other drugs) Exclusion Criteria:

  • Patients with a diagnosis of COPD

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • AstraZeneca
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Pascal Piedbois, Study Director, AstraZeneca

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.